Pharma BD Deal Intelligence
Cubist Pharmaceuticals, Inc. / Adolor Corporation
2011 · Acquisition/Merger · $415M · Complete
Announcement Sentiment
88
Strongly positive
Cubist acquired Adolor for $4.25/share (~$190M cash) plus CPRs of up to $4.50/share tied to ADL5945 milestones, total up to $415M. Deal added marketed Entereg and a Phase 2 OIC candidate to Cubist's hospital franchise.
Did it work? Outcome assessment Strategic verdict
Partially Achieved
Financial impact
Impaired/Written Down
Assessment window: 10yr post-close.
Key facts
Announced Oct 24, 2011 Closed Dec 12, 2011 Deal value $415M Deal type Acquisition/Merger Therapeutic area Postoperative ileus; opioid-induced constipation Indications Postoperative ileus; opioid-induced constipation Key assets Entereg (alvimopan); ADL5945 Mechanism Peripherally acting mu-opioid receptor antagonists
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About